SEC Form 4 · accession 0000891293-15-000018
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
May 4, 2015
Accepted (ET)
May 4, 2015 · 6:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 4, 2015 | S | 3,700 | $1.85 | D | 708,040 | D | |
| Common Stock | May 4, 2015 | S | 2,700 | $1.855 | D | 705,340 | D | |
| Common Stock | May 4, 2015 | S | 3,000 | $1.86 | D | 702,340 | D | |
| Common Stock | May 4, 2015 | S | 600 | $1.865 | D | 701,740 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.